Nexalin Technology Announces Fourth Peer-Reviewed Publication in Alzheimer’s Disease: 15 mA DIFS™ Significantly Improves Sleep Quality in Patients with Mild Alzheimer’s Disease October 27, 2026
Nexalin Technology Regains Compliance with Nasdaq Minimum Bid Price Requirement; Nasdaq Hearings Panel Grants Request for Continued Listing October 8, 2026
Nexalin Technology Signs Definitive Exclusive Distribution and Local Manufacturing Agreement for Brazil and South America, Marking a Major Step in its Transition Toward Commercial Revenue Generation October 1, 2026